Elsubrutinib,Upadacitinib,ABBV-599
AbbVie
['elsubrutinib', 'pani ', ' ola ', 'upadacitinib']
in a phase 2 trial, both monotherapy with 30mg upadacitinib and combo therapy with the btk inhibitor elsubrutinib met the primary endpoint (sri-4 and less than 10mg gc at wk 24) vs placebo in patients with #sle. #eular2023 
The #LancetRheumatology is a clinical #rheumatology journal publishing innovative & practice-changing research & opinion across all #rheumatic & #MSK disorders